{"id":356509,"date":"2019-04-17T07:25:03","date_gmt":"2019-04-17T07:25:03","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=356509"},"modified":"2019-04-17T07:25:03","modified_gmt":"2019-04-17T07:25:03","slug":"cancer-immunotherapies-market-2019-global-trends-market-share-industry-size-growth-opportunities-and-forecast-to-2024","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cancer-immunotherapies-market-2019-global-trends-market-share-industry-size-growth-opportunities-and-forecast-to-2024_356509.html","title":{"rendered":"Cancer Immunotherapies Market 2019 Global Trends, Market Share, Industry Size, Growth, Opportunities and Forecast to 2024"},"content":{"rendered":"
\n
“Cancer Immunotherapies Market”<\/div>\n<\/div>\n
WiseGuyReports.com adds \u201cCancer Immunotherapies Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024\u201d reports to its database<\/div>\n

Summary<\/strong><\/p>\n

WiseGuyReports.com<\/strong> adds “Cancer Immunotherapies Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024<\/strong>” reports to its database.<\/p>\n

Cancer immunotherapy, also called biologic therapy, which can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body’s immune system to attack tumours. 
The global Cancer Immunotherapies market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cancer Immunotherapies market based on company, product type, end user and key regions.<\/p>\n

This report studies the global market size of Cancer Immunotherapies<\/strong><\/a> in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Immunotherapies in these regions. 
This research report categorizes the global Cancer Immunotherapies market by top players\/brands, region, type and end user. This report also studies the global Cancer Immunotherapies market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.<\/p>\n

The following manufacturers are covered in this report, with sales, revenue, market share for each company: 
Amgen 
AstraZeneca 
Roche 
Bristol-Myers Squibb 
Bayer 
Merck 
ARMO BioSciences (Eli Lilly) 
Novartis 
Pfizer 
Johnson & Johnson 
AbbVie 
Gilead Sciences<\/strong><\/p>\n

Request a Free Sample Report @ <\/strong>https:\/\/www.wiseguyreports.com\/sample-request\/3925109-global-cancer-immunotherapies-market-insights-forecast-to-2025<\/strong><\/a><\/p>\n

Market size by Product 
<\/strong>Monoclonal Antibodies (MABs) 
Cancer Vaccines 
Immunomodulators 
Adoptive Cell transfer 
Checkpoint Inhibitors 
Market size by End User 
Breast Cancer 
Leukemia 
Lymphoma 
Melanoma 
Colorectal Cancer 
Non-Small Cell Lung Cancer<\/p>\n

Market size by Region 
<\/strong>North America 
United States 
Canada 
Mexico 
Asia-Pacific 
China 
India 
Japan 
South Korea 
Australia 
Indonesia 
Singapore 
Malaysia 
Philippines 
Thailand 
Vietnam 
Europe 
Germany 
France 
UK 
Italy 
Spain 
Russia 
Central & South America 
Brazil 
Rest of Central & South America 
Middle East & Africa 
GCC Countries 
Turkey 
Egypt 
South Africa<\/p>\n

The study objectives of this report are: 
<\/strong>To study and analyze the global Cancer Immunotherapies market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025. 
To understand the structure of Cancer Immunotherapies market by identifying its various subsegments. 
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). 
Focuses on the key global Cancer Immunotherapies companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development. 
To project the value and sales volume of Cancer Immunotherapies submarkets, with respect to key regions. 
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.<\/p>\n

In this study, the years considered to estimate the market size of Cancer Immunotherapies are as follows: 
<\/strong>History Year: 2014-2018 
Base Year: 2018 
Estimated Year: 2019 
Forecast Year 2019 to 2025<\/p>\n

At Any Query @ <\/strong>https:\/\/www.wiseguyreports.com\/enquiry\/3925109-global-cancer-immunotherapies-market-insights-forecast-to-2025<\/strong><\/a><\/p>\n

Major Key Points in Table of Content<\/strong><\/p>\n

1 Study Coverage 
<\/strong>1.1 Cancer Immunotherapies Product 
1.2 Market Segments 
1.3 Key Manufacturers Covered 
1.4 Market by Type 
1.4.1 Global Cancer Immunotherapies Market Size Growth Rate by Product 
1.4.2 Monoclonal Antibodies (MABs) 
1.4.3 Cancer Vaccines 
1.4.4 Immunomodulators 
1.4.5 Adoptive Cell transfer 
1.4.6 Checkpoint Inhibitors 
1.5 Market by End User 
1.5.1 Global Cancer Immunotherapies Market Size Growth Rate by End User 
1.5.2 Breast Cancer 
1.5.3 Leukemia 
1.5.4 Lymphoma 
1.5.5 Melanoma 
1.5.6 Colorectal Cancer 
1.5.7 Non-Small Cell Lung Cancer 
1.6 Study Objectives 
1.7 Years Considered<\/p>\n

2 Executive Summary 
<\/strong>2.1 Global Cancer Immunotherapies Market Size 
2.1.1 Global Cancer Immunotherapies Revenue 2014-2025 
2.1.2 Global Cancer Immunotherapies Sales 2014-2025 
2.2 Cancer Immunotherapies Growth Rate by Regions 
2.2.1 Global Cancer Immunotherapies Sales by Regions 
2.2.2 Global Cancer Immunotherapies Revenue by Regions<\/p>\n

….<\/strong><\/p>\n

11 Company Profiles 
11.1 Amgen 
<\/strong>11.1.1 Amgen Company Details 
11.1.2 Company Business Overview 
11.1.3 Amgen Cancer Immunotherapies Sales, Revenue and Gross Margin (2014-2019) 
11.1.4 Amgen Cancer Immunotherapies Products Offered 
11.1.5 Amgen Recent Development 
11.2 AstraZeneca 
<\/strong>11.2.1 AstraZeneca Company Details 
11.2.2 Company Business Overview 
11.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue and Gross Margin (2014-2019) 
11.2.4 AstraZeneca Cancer Immunotherapies Products Offered 
11.2.5 AstraZeneca Recent Development 
11.3 Roche 
11.3.1 Roche Company Details 
<\/strong>11.3.2 Company Business Overview 
11.3.3 Roche Cancer Immunotherapies Sales, Revenue and Gross Margin (2014-2019) 
11.3.4 Roche Cancer Immunotherapies Products Offered 
11.3.5 Roche Recent Development 
11.4 Bristol-Myers Squibb 
<\/strong>11.4.1 Bristol-Myers Squibb Company Details 
11.4.2 Company Business Overview 
11.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue and Gross Margin (2014-2019) 
11.4.4 Bristol-Myers Squibb Cancer Immunotherapies Products Offered 
11.4.5 Bristol-Myers Squibb Recent Development 
11.5 Bayer 
<\/strong>11.5.1 Bayer Company Details 
11.5.2 Company Business Overview 
11.5.3 Bayer Cancer Immunotherapies Sales, Revenue and Gross Margin (2014-2019) 
11.5.4 Bayer Cancer Immunotherapies Products Offered 
11.5.5 Bayer Recent Development 
11.6 Merck 
<\/strong>11.6.1 Merck Company Details 
11.6.2 Company Business Overview 
11.6.3 Merck Cancer Immunotherapies Sales, Revenue and Gross Margin (2014-2019) 
11.6.4 Merck Cancer Immunotherapies Products Offered 
11.6.5 Merck Recent Development 
11.7 ARMO BioSciences (Eli Lilly) 
<\/strong>11.7.1 ARMO BioSciences (Eli Lilly) Company Details 
11.7.2 Company Business Overview 
11.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue and Gross Margin (2014-2019) 
11.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Products Offered 
11.7.5 ARMO BioSciences (Eli Lilly) Recent Development 
11.8 Novartis 
<\/strong>11.8.1 Novartis Company Details 
11.8.2 Company Business Overview 
11.8.3 Novartis Cancer Immunotherapies Sales, Revenue and Gross Margin (2014-2019) 
11.8.4 Novartis Cancer Immunotherapies Products Offered 
11.8.5 Novartis Recent Development 
11.9 Pfizer 
<\/strong>11.9.1 Pfizer Company Details 
11.9.2 Company Business Overview 
11.9.3 Pfizer Cancer Immunotherapies Sales, Revenue and Gross Margin (2014-2019) 
11.9.4 Pfizer Cancer Immunotherapies Products Offered 
11.9.5 Pfizer Recent Development 
11.10 Johnson & Johnson 
<\/strong>11.10.1 Johnson & Johnson Company Details 
11.10.2 Company Business Overview 
11.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue and Gross Margin (2014-2019) 
11.10.4 Johnson & Johnson Cancer Immunotherapies Products Offered 
11.10.5 Johnson & Johnson Recent Development 
11.11 AbbVie 
11.12 Gilead Sciences<\/strong><\/p>\n

Continued….<\/strong><\/p>\n

Contact Us: sales@wiseguyreports.com<\/strong><\/p>\n

Ph: +1-646-845-9349 (US); Ph: +44 208 133 9349 (UK)<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com<\/a>
Contact Person:<\/strong> Norah Trent
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> https:\/\/www.wiseguyreports.com\/sample-request\/3925109-global-cancer-immunotherapies-market-insights-forecast-to-2025<\/a><\/p>\n

 <\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Cancer Immunotherapies Market” WiseGuyReports.com adds \u201cCancer Immunotherapies Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024\u201d reports to its database Summary WiseGuyReports.com adds “Cancer Immunotherapies Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-356509","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/356509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=356509"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/356509\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=356509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=356509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=356509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}